Matthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell ...

It is conceivable that the treated B cells activate macrophages and natural killer cells of the immune system in this way. The research team will now clarify whether this assumption is correct in ...

In collaborative work, Trethera and the Peter Clark Lab at UCLA have shown that when autoreactive T and B cells divide, they activate the TRE-515 target dCK. In those abnormally activated cells, dCK ...